Samarth Kulkarni - 12 Jun 2025 Form 4 Insider Report for Black Diamond Therapeutics, Inc. (BDTX)

Role: Director
Signature: /s/ Brent Hatzis-Schoch, Attorney-in-Fact
Issuer symbol: BDTX
Transactions as of: 12 Jun 2025
Net transactions value: $0
Form type: 4
Filing time: 12 Jun 2025, 18:22:19 UTC
Previous filing: 03 Jun 2025
Next filing: 24 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Kulkarni Samarth	Director	C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE	/s/ Brent Hatzis-Schoch, Attorney-in-Fact	12 Jun 2025	0001682019

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BDTX	Stock Option (Right to Buy)	Award	$0	+30,550		$0.000000	30,550	12 Jun 2025	Common Stock	30,550	$2.43	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 12, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.